
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ART4
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Arnatar’s ART4 Wins FDA Orphan And Rare Pediatric Disease Designations
Details : ART4 is designed to address the root cause of ALGS by upregulating endogenous JAG1 protein expression and is designed for once-monthly subcutaneous dosing.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 25, 2025
Lead Product(s) : ART4
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
